What question did this study set out to answer?

To determine the optimal initial relative dose intensity of modified FOLFIRINOX for treating pancreatic ductal adenocarcinoma.

April 15, 2026Open Access

Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort

Key Points

To determine the optimal initial relative dose intensity of modified FOLFIRINOX for treating pancreatic ductal adenocarcinoma.
Conducted a retrospective multi-center cohort study
Analyzed treatment data of Taiwanese PDAC patients
Assessed efficacy and tolerability associated with various initial dose intensities.
An initial relative dose intensity of 70-90% for irinotecan and oxaliplatin was optimal.
Patients experienced improved efficacy and tolerability at this dose range.

Abstract

The initial RDI of 70-90% for irinotecan and oxaliplatin may optimize both efficacy and tolerability in Taiwanese PDAC patients treated with FOLFIRINOX.

Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort

Key Points

Abstract

Cite This Study

Also Consider

Also Consider